NEXI1EUR
Neximmune, Inc.
A clinical-stage biotech company working on cell therapies to treat cancer, Neximmune grows immune cells called NK cells in the lab and engineers them to attack tumors. The technology grew out of research at the National Cancer Institute, and the company was co-founded in 2015 by NIH physician-scientist Richard Childs, who spent his career studying natural killer cells. The name itself pairs "next" with "immune," hinting at its bet on the body's own defenders.
CUSIP: 65344D109HealthcareUS1 holder